Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
State of the art in intravesical therapy for lower urinary tract symptoms.

Reviews in urology

Kaufman J, Tyagi V, Anthony M, Chancellor MB, Tyagi P.
PMID: 21234261
Rev Urol. 2010;12(4):e181-9.

Intravesical therapy is the routine first-line treatment for effectively delaying or preventing the recurrence of bladder cancer. This route of drug administration has also shown tremendous promise in the treatment of interstitial cystitis/painful bladder syndrome (IC/PBS) and potentially overactive...

Cite
Kaufman J, Tyagi V, Anthony M, et al. State of the art in intravesical therapy for lower urinary tract symptoms. Rev Urol. 2010;12(4):e181-9
Kaufman, J., Tyagi, V., Anthony, M., Chancellor, M. B., & Tyagi, P. (2010). State of the art in intravesical therapy for lower urinary tract symptoms. Reviews in urology, 12(4), e181-9.
Kaufman, Jonathan, et al. "State of the art in intravesical therapy for lower urinary tract symptoms." Reviews in urology vol. 12,4 (2010): e181-9.
Kaufman J, Tyagi V, Anthony M, Chancellor MB, Tyagi P. State of the art in intravesical therapy for lower urinary tract symptoms. Rev Urol. 2010;12(4):e181-9. PMID: 21234261; PMCID: PMC3020280.
Copy Download .nbib Format: NLM
Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs.

Journal of pharmacy & bioallied sciences

Guarnieri M, Tyler BM, Detolla L, Zhao M, Kobrin B.
PMID: 24459402
J Pharm Bioallied Sci. 2014 Jan;6(1):38-42. doi: 10.4103/0975-7406.124315.

BACKGROUND: Long-acting therapy in laboratory animals offers advantages over the current practice of 2-3 daily drug injections. Yet little is known about the disintegration of biodegradable drug implants in rodents.OBJECTIVE: Compare bioavailability of buprenorphine with the biodegradation of lipid-encapsulated...

Cite
Guarnieri M, Tyler BM, Detolla L, et al. Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs. J Pharm Bioallied Sci. 2014;6(1):38-42doi: 10.4103/0975-7406.124315.
Guarnieri, M., Tyler, B. M., Detolla, L., Zhao, M., & Kobrin, B. (2014). Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs. Journal of pharmacy & bioallied sciences, 6(1), 38-42. https://doi.org/10.4103/0975-7406.124315
Guarnieri, Michael, et al. "Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs." Journal of pharmacy & bioallied sciences vol. 6,1 (2014): 38-42. doi: https://doi.org/10.4103/0975-7406.124315
Guarnieri M, Tyler BM, Detolla L, Zhao M, Kobrin B. Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs. J Pharm Bioallied Sci. 2014 Jan;6(1):38-42. doi: 10.4103/0975-7406.124315. PMID: 24459402; PMCID: PMC3895292.
Copy Download .nbib Format: NLM
Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye.

ACS applied bio materials

He X, Yuan Z, Gaeke S, Kao WW, Li SK, Miller D, Williams B, Park YC.
PMID: 35014495
ACS Appl Bio Mater. 2021 Feb 15;4(2):1461-1469. doi: 10.1021/acsabm.0c01334. Epub 2021 Jan 22.

To treat chronic posterior eye diseases, frequent intravitreal injections or sustained-release drug implants are the current standard of care. Sustained-release drug implants often involve burst release of the drugs and the dosage from the implants cannot be controlled after...

Cite
He X, Yuan Z, Gaeke S, et al. Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye. ACS Appl Bio Mater. 2021;4(2):1461-1469doi: 10.1021/acsabm.0c01334.
He, X., Yuan, Z., Gaeke, S., Kao, W. W., Li, S. K., Miller, D., Williams, B., & Park, Y. C. (2021). Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye. ACS applied bio materials, 4(2), 1461-1469. https://doi.org/10.1021/acsabm.0c01334
He, Xingyu, et al. "Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye." ACS applied bio materials vol. 4,2 (2021): 1461-1469. doi: https://doi.org/10.1021/acsabm.0c01334
He X, Yuan Z, Gaeke S, Kao WW, Li SK, Miller D, Williams B, Park YC. Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye. ACS Appl Bio Mater. 2021 Feb 15;4(2):1461-1469. doi: 10.1021/acsabm.0c01334. Epub 2021 Jan 22. PMID: 35014495.
Copy Download .nbib Format: NLM
Size-Exclusive Nanoporous Biodegradable PLGA Capsules for Drug Delivery Implants and In Vivo Stability in the Posterior Segment.

ACS applied bio materials

He X, Yuan Z, Kao W, Miller D, Li SK, Park YC.
PMID: 35021661
ACS Appl Bio Mater. 2020 Mar 16;3(3):1722-1729. doi: 10.1021/acsabm.0c00027. Epub 2020 Feb 25.

The current standard of care for posterior segment eye diseases, such as neovascular age-related macular degeneration, diabetic macular edema, is frequent intravitreal injections or sustained-release drug implants. Intravitreal injections have a low incidence of serious complications such as retinal...

Cite
He X, Yuan Z, Kao W, et al. Size-Exclusive Nanoporous Biodegradable PLGA Capsules for Drug Delivery Implants and In Vivo Stability in the Posterior Segment. ACS Appl Bio Mater. 2020;3(3):1722-1729doi: 10.1021/acsabm.0c00027.
He, X., Yuan, Z., Kao, W., Miller, D., Li, S. K., & Park, Y. C. (2020). Size-Exclusive Nanoporous Biodegradable PLGA Capsules for Drug Delivery Implants and In Vivo Stability in the Posterior Segment. ACS applied bio materials, 3(3), 1722-1729. https://doi.org/10.1021/acsabm.0c00027
He, Xingyu, et al. "Size-Exclusive Nanoporous Biodegradable PLGA Capsules for Drug Delivery Implants and In Vivo Stability in the Posterior Segment." ACS applied bio materials vol. 3,3 (2020): 1722-1729. doi: https://doi.org/10.1021/acsabm.0c00027
He X, Yuan Z, Kao W, Miller D, Li SK, Park YC. Size-Exclusive Nanoporous Biodegradable PLGA Capsules for Drug Delivery Implants and In Vivo Stability in the Posterior Segment. ACS Appl Bio Mater. 2020 Mar 16;3(3):1722-1729. doi: 10.1021/acsabm.0c00027. Epub 2020 Feb 25. PMID: 35021661.
Copy Download .nbib Format: NLM
Safety, Quality, and Acceptability of Contraceptive Subdermal Implant Provision by Community Health Extension Workers Versus Nurses and Midwives in Nigeria: Protocol for a Quasi-Experimental, Noninferiority Study.

JMIR research protocols

Reiss K, Penfold S, Alabi O, Ali M, Hopkins K, Ngo TD, Odogwu K, Douthwaite M, Ezire O, Udoh U, Effiom E, Munroe ES.
PMID: 29500162
JMIR Res Protoc. 2018 Mar 02;7(3):e67. doi: 10.2196/resprot.8721.

BACKGROUND: As part of its Family Planning 2020 commitment, the Nigerian government is aiming for a contraceptive prevalence rate of 36% by 2018, and in 2014, approved a policy to allow community health extension workers (CHEWs), in addition to...

Cite
Reiss K, Penfold S, Alabi O, et al. Safety, Quality, and Acceptability of Contraceptive Subdermal Implant Provision by Community Health Extension Workers Versus Nurses and Midwives in Nigeria: Protocol for a Quasi-Experimental, Noninferiority Study. JMIR Res Protoc. 2018;7(3):e67doi: 10.2196/resprot.8721.
Reiss, K., Penfold, S., Alabi, O., Ali, M., Hopkins, K., Ngo, T. D., Odogwu, K., Douthwaite, M., Ezire, O., Udoh, U., Effiom, E., & Munroe, E. S. (2018). Safety, Quality, and Acceptability of Contraceptive Subdermal Implant Provision by Community Health Extension Workers Versus Nurses and Midwives in Nigeria: Protocol for a Quasi-Experimental, Noninferiority Study. JMIR research protocols, 7(3), e67. https://doi.org/10.2196/resprot.8721
Reiss, Kate, et al. "Safety, Quality, and Acceptability of Contraceptive Subdermal Implant Provision by Community Health Extension Workers Versus Nurses and Midwives in Nigeria: Protocol for a Quasi-Experimental, Noninferiority Study." JMIR research protocols vol. 7,3 (2018): e67. doi: https://doi.org/10.2196/resprot.8721
Reiss K, Penfold S, Alabi O, Ali M, Hopkins K, Ngo TD, Odogwu K, Douthwaite M, Ezire O, Udoh U, Effiom E, Munroe ES. Safety, Quality, and Acceptability of Contraceptive Subdermal Implant Provision by Community Health Extension Workers Versus Nurses and Midwives in Nigeria: Protocol for a Quasi-Experimental, Noninferiority Study. JMIR Res Protoc. 2018 Mar 02;7(3):e67. doi: 10.2196/resprot.8721. PMID: 29500162; PMCID: PMC5856922.
Copy Download .nbib Format: NLM
Biobased Ionic Liquids as Multitalented Materials in Lipidic Drug Implants.

Pharmaceutics

Júlio A, Sultane A, Viana AS, Mota JP, Santos de Almeida T.
PMID: 34452124
Pharmaceutics. 2021 Jul 28;13(8). doi: 10.3390/pharmaceutics13081163.

Lipidic implants are valuable controlled delivery systems that present good biocompatibility and are useful for long-lasting therapies. However, these promising systems can present inflexible drug release profiles that limit their performance. Thus, finding new materials to overcome this drawback...

Cite
Júlio A, Sultane A, Viana AS, et al. Biobased Ionic Liquids as Multitalented Materials in Lipidic Drug Implants. Pharmaceutics. 2021;13(8)doi: 10.3390/pharmaceutics13081163.
Júlio, A., Sultane, A., Viana, A. S., Mota, J. P., & Santos de Almeida, T. (2021). Biobased Ionic Liquids as Multitalented Materials in Lipidic Drug Implants. Pharmaceutics, 13(8), . https://doi.org/10.3390/pharmaceutics13081163
Júlio, Ana, et al. "Biobased Ionic Liquids as Multitalented Materials in Lipidic Drug Implants." Pharmaceutics vol. 13,8 (2021). doi: https://doi.org/10.3390/pharmaceutics13081163
Júlio A, Sultane A, Viana AS, Mota JP, Santos de Almeida T. Biobased Ionic Liquids as Multitalented Materials in Lipidic Drug Implants. Pharmaceutics. 2021 Jul 28;13(8). doi: 10.3390/pharmaceutics13081163. PMID: 34452124; PMCID: PMC8401770.
Copy Download .nbib Format: NLM
Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice.

Journal of veterinary medicine

DeTolla L, Sanchez R, Khan E, Tyler B, Guarnieri M.
PMID: 26464927
J Vet Med. 2014;2014:365673. doi: 10.1155/2014/365673. Epub 2014 Nov 27.

Subcutaneous drug implants are convenient systems for the long-term delivery of drugs in animals. Lipid carriers are logical tools because they generally allow for higher doses and low toxicity. The present study used an US Food and Drug Administration...

Cite
DeTolla L, Sanchez R, Khan E, et al. Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice. J Vet Med. 2014;2014:365673doi: 10.1155/2014/365673.
DeTolla, L., Sanchez, R., Khan, E., Tyler, B., & Guarnieri, M. (2014). Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice. Journal of veterinary medicine, 2014365673. https://doi.org/10.1155/2014/365673
DeTolla, L, et al. "Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice." Journal of veterinary medicine vol. 2014 (2014): 365673. doi: https://doi.org/10.1155/2014/365673
DeTolla L, Sanchez R, Khan E, Tyler B, Guarnieri M. Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice. J Vet Med. 2014;2014:365673. doi: 10.1155/2014/365673. Epub 2014 Nov 27. PMID: 26464927; PMCID: PMC4590835.
Copy Download .nbib Format: NLM
Drug Implants of Hydrogels via Collective Behavior of Microgel Colloids for On-Demand Cancer Therapy.

ACS applied bio materials

Wang Y, Wang L, Yan M, Feng L, Dong S, Hao J.
PMID: 35026926
ACS Appl Bio Mater. 2019 Apr 15;2(4):1531-1541. doi: 10.1021/acsabm.8b00823. Epub 2019 Mar 07.

In nature, the collective behaviors such as the growth of bacteria and the cooperation of insects possess great superiority and can create functional materials through diversified interactions for accomplishing complex tasks that cannot be performed by a single unit....

Cite
Wang Y, Wang L, Yan M, et al. Drug Implants of Hydrogels via Collective Behavior of Microgel Colloids for On-Demand Cancer Therapy. ACS Appl Bio Mater. 2019;2(4):1531-1541doi: 10.1021/acsabm.8b00823.
Wang, Y., Wang, L., Yan, M., Feng, L., Dong, S., & Hao, J. (2019). Drug Implants of Hydrogels via Collective Behavior of Microgel Colloids for On-Demand Cancer Therapy. ACS applied bio materials, 2(4), 1531-1541. https://doi.org/10.1021/acsabm.8b00823
Wang, Yitong, et al. "Drug Implants of Hydrogels via Collective Behavior of Microgel Colloids for On-Demand Cancer Therapy." ACS applied bio materials vol. 2,4 (2019): 1531-1541. doi: https://doi.org/10.1021/acsabm.8b00823
Wang Y, Wang L, Yan M, Feng L, Dong S, Hao J. Drug Implants of Hydrogels via Collective Behavior of Microgel Colloids for On-Demand Cancer Therapy. ACS Appl Bio Mater. 2019 Apr 15;2(4):1531-1541. doi: 10.1021/acsabm.8b00823. Epub 2019 Mar 07. PMID: 35026926.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries